Placebo and the Helsinki Declaration--what to do?

Area of Science:

• Medical Ethics
• Clinical Trial Design
• Research Regulations

Background:

• The Helsinki Declaration is a key ethical guideline for human research.
• Recent revisions retain controversial articles despite ethical debates.
• The "best treatment" stipulation complicates placebo use in controlled studies.

Purpose of the Study:

• To analyze the ethical implications of the Helsinki Declaration's stipulations on placebo use.
• To evaluate the impact of specific articles on the scientific validity of clinical trials.
• To discuss the conditions under which placebo use remains ethically justifiable.

Main Methods:

• Review of the Helsinki Declaration's historical revisions and key articles.
• Ethical analysis of the "best treatment" requirement versus placebo controls.
• Examination of scientific and ethical justifications for placebo-controlled trials.

Main Results:

• Certain articles in the Helsinki Declaration remain unchanged, posing challenges to modern research.
• The "best treatment" rule restricts the use of placebos, potentially impeding drug and treatment evaluation.
• Placebo use is deemed ethically permissible when it avoids irreversible harm or significant suffering.

Conclusions:

• The Helsinki Declaration's rigidity on treatment standards requires re-evaluation for ethical placebo use.
• Placebo-controlled trials are essential for evaluating numerous treatments, particularly for conditions with psychological components or spontaneous remission.
• Balancing ethical principles with scientific rigor is crucial for advancing medical knowledge.